NEW YORK (GenomeWeb News) – Predictive Biosciences has appointed two new vice presidents, including James Groves, who will be VP of lab operations, and Mark Smith as VP of information technology.
Groves, who was head of operations at SED Medical Laboratories and VP of clinical operations at the Beijing International Heart Institute, will work on strategic sales and growth of the OncoDiagnostics Laboratory. Smith recently was VP of information technology at Athena Diagnostics, where he was responsible for the firm's IT strategy and development of it customer interface systems.
Amit Meller, an associate professor of biomedical engineering and physics at BU, is a founder of NobleGen Biosciences, a new startup that aims to commercialize nanopore sequencing technology that he developed. His co-founders are Ory Zik, a serial entrepreneur, and Zeev Pearl, an intellectual property lawyer.
Frank Feist is the founding CEO of NobleGen. Most recently, he headed the commercial team of Advalytix, which was acquired by Olympus in 2005 and became part of Beckman Coulter last year.
Phil Buzby recently joined NobleGen as vice president of biochemistry. Until 2008, he was a senior director of intellectual property at Helicos BioSciences, and before that, a senior director of nucleic acid chemistry at Helicos.
IntegenX has named Debi Frost to be the company's VP of operations. Frost spent over 20 years at Applied Biosystems, including serving as VP of global nucleotide operations and VP of customer services and distribution.
Exosome Diagnostics has named its board of directors, which includes Georg Negben and Peter Johan, both of NGN Capital, Geert-Jan Mulder and James McCullough of Forbion Capital, and continuing board member Joe Boystak.
NGN's Bernard Peperstraete and Forbion's Marco Doorsma have been appointed as observers to the board.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.